Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Next webinar: Tobacco & Lung Cancer's Shared History, and Practical Approaches to Quitting
Dr West
Author
Howard (Jack) West, MD

More Doctors Smoke Camels

Our next webinar, at 6 PM Eastern/3 PM Pacific on Wednesday, December 7th, will feature Dr Mark Millard, Medical Director of the Baylor Martha Foster Lung Care Center and Professor of Pulmonology at Baylor University Medical Center, speaking on the history of tobacco's association with lung cancer, and the current tools to help people quit smoking. Of course, the association of smoking with lung cancer is a sensitive topic, leading to all too much stigma and blame. It doesn't cause all lung cancer, but it is the leading risk factor, and tobacco is also associated with markedly increased risk of other cancers and many other medical problems. Dr. Millard provides a truly interesting and thoughtful review of the subject.

He'll also cover the range of practical options available to help people quit smoking. We should all be aware of the powerful addiction caused by nicotine (yes, my own mother has been a smoker for more than 50 years, and not because she doesn't want to quit), but people can beat it: This lowers their risk of lung cancer and other medical issues readily, and for those fighting lung cancer, it can improve their treatment outcomes. It's never too late to quit, so learn more about the options, for yourself or someone you care about.

The approximately 30-40 minute presentation will be follwed by a question and answer session, so feel free to jump in with a relevant question.

This webinar is part of an ongoing series produced by GRACE in partnership with the LUNGevity Foundation. All of the live webinars are free (learn more and register here), and they are all edited into free podcasts later.

We hope you'll join us on December 7th.

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on